Skip to main content

Table 2 Gout related treatment patterns overall and by presence of comorbidities

From: Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

Gout-related medication

Ever use during 1 year after gout diagnosis

 

All

No comorbidities

(n = 74,356)

Cardiometabolic§

(n = 64,385)

 

Diabetes

(n = 26,818)

Chronic renal impairment

(n = 5,718)

ALL

n

%

n

%

n

%

p-value*

n

%

n

%

NSAIDS

74,055

41.7%

32,701

44.0%

25,994

40.4%

0.022

9,592

35.8%

1,134

19.8%

selective

12,455

7.0%

4,102

5.5%

5,077

7.9%

< .0001

1,942

7.2%

219

3.8%

nonselective

68,826

38.7%

31,167

41.9%

23,765

36.9%

0.173

8,660

32.3%

1,001

17.5%

Colchicine

29,686

16.7%

11,595

15.6%

11,327

17.6%

< .0001

4,950

18.5%

1,559

27.3%

Corticosteroids

37,224

21.0%

14,182

19.1%

14,476

22.5%

< .0001

5,153

19.2%

1,617

28.3%

Probenecid

2,510

1.4%

1,108

1.5%

901

1.4%

0.249

331

1.2%

58

1.0%

Allopurinol

56,544

31.8%

23,215

31.2%

20,971

32.6%

< .0001

9,183

34.2%

2,512

43.9%

No treatment

69,241

39.0%

29,202

39.3%

24,938

38.7%

< .0001

10,669

39.8%

2,171

38.0%

FEMALES

N = 43,304

N = 12,387

N = 17,418

 

N = 9,381

N = 2,025

NSAIDS

16,183

37.4%

4,641

37.5%

6,464

37.1%

< .0001

3,279

35.0%

368

18.2%

   selective

3,815

8.8%

911

7.4%

1,643

9.4%

< .0001

769

8.2%

77

3.8%

   nonselective

14,423

33.3%

4,255

34.4%

5,684

32.6%

0.000

2,899

30.9%

320

15.8%

Colchicine

5,096

11.8%

890

7.2%

2,312

13.3%

< .0001

1,558

16.6%

483

23.9%

Corticosteroids

9,831

22.7%

2,438

19.7%

4,213

24.2%

< .0001

1,954

20.8%

575

28.4%

Probenecid

441

1.0%

96

0.8%

195

1.1%

0.359

115

1.2%

27

1.3%

Allopurinol

8,905

20.6%

1,676

13.5%

4,006

23.0%

< .0001

2,692

28.7%

834

41.2%

No treatment

19,637

45.3%

6,200

50.1%

7,693

44.2%

< .0001

3,991

42.5%

816

40.3%

MALES

N = 134,333

N = 61,969

N = 46,967

 

N = 17,437

N = 3,693

NSAIDS

57,872

43.1%

28,060

45.3%

19,530

41.6%

0.575

6,313

36.2%

766

20.7%

   selective

8,640

6.4%

3,191

5.1%

3,434

7.3%

< .0001

1,173

6.7%

142

3.8%

   nonselective

54,403

40.5%

26,912

43.4%

18,081

38.5%

0.012

5,761

33.0%

681

18.4%

Colchicine

24,590

18.3%

10,705

17.3%

9,015

19.2%

< .0001

3,392

19.5%

1,076

29.1%

Corticosteroids

27,393

20.4%

11,744

19.0%

10,263

21.9%

< .0001

3,199

18.3%

1,042

28.2%

Probenecid

2,069

1.5%

1,012

1.6%

706

1.5%

0.260

216

1.2%

31

0.8%

Allopurinol

47,639

35.5%

21,539

34.8%

16,965

36.1%

< .0001

6,491

37.2%

1,678

45.4%

No treatment

49,604

36.9%

23,002

37.1%

17,245

36.7%

< .0001

6,678

38.3%

1,355

36.7%

  1. § Cardiometabolic disease include congestive heart failure, ischaemic heart disease, hypertension, cerebrovascular disease, peripheral arterial disease, dyslipidemia.
  2. * P-value from logistic model with drug as outcome associated to cardiometabolic comorbidities vs no comorbidities adjusting for age in categories (20-49, 50-59, 60-69, 70-79, 80-89).
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us